Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation

Endocrinology

Volumn 150, Issue 1, 2009, Pages 5-13

  Idris, Aymen I ^a   Greig, Iain R ^b   Bassonga Landao, Euphemie ^a   Ralston, Stuart H ^a   Van't Hof, Rob J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABD 34; ABD 350; ABD 56; ABD 68; ALENDRONIC ACID; CARBOXYLIC ACID DERIVATIVE; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW; CALVARIA; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; IC 50; MACROPHAGE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL;

ALENDRONATE; ANIMALS; ANIMALS, NEWBORN; BENZOATES; BIPHENYL COMPOUNDS; BONE MARROW CELLS; BONE RESORPTION; FEMALE; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OVARIECTOMY; PARATHYROID HORMONE; SKULL;

EID: 58149465878     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0998     Document Type: Article

References (31)

1. Kanis JA 2002 Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936
2. Helfrich MH 2003 Osteoclast diseases. Microsc Res Tech 61:514-532
3. Guise TA, Mundy GR 1998 Cancer and bone. Endocr Rev 19:18-54
4. Rodan GA, Martin TJ 2000 Therapeutic approaches to bone diseases. Science 289:1508-1514
5. Eastell R 1998 Treatment of postmenopausal osteoporosis, N Engl J Med 338:736-746
6. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610
7. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353: 555-565
8. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751
9. van 't Hof RJ, Idris AI, Ridge SA, Dunford J, Greig IR, Ralston SH 2004 Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors. J Bone Miner Res 19:1651-1660
10. Idris AI, Mrak E, Greig IR, Guidobono F, Ralston SH, van 't Hof R 2008 ABD56 causes osteoclast apoptosis by inhibiting the NF κB and ERK pathways. Biochem Biophys Res Commun 371:94-99
11. Giagoudakis G, Markantonis SL 1998 An alternative high-performance liquid chromatographic method for the determination of diclofenac and flurbiprofen in plasma. J Pharm Biomed Anal 17:897-901
12. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH 2005 Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11:774-779
13. van 't Hof RJ, von Lindern M, Nijweide PJ, Beug H 1997 Stem cell factor stimulates chicken osteoclast activity in vitro, FASEB J 11:287-293
14. van 't Hof RJ 2003 Osteoclast formation in the mouse coculture assay. In: Helfrich MH, Ralston SH, eds. Bone research protocols. 1st ed. Totowa, NJ: Humana Press; 145-152
15. Stewart TL, Roschger P, Misof BM, Mann V, Fratzl P, Klaushofer K, Aspden RM, Ralston SH 2005 Association of COLIA1 Sp1 alleles with defective bone nodule formation in vitro and abnormal bone mineralisation in vivo. Calcif Tiss Int 77:113-118
16. Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM, Ralston SH 2001 Defective bone formation and anabolic responses to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 142:760-766
17. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
18. Ralston SH, Coleman R, Fraser WD, Gallagher SJ, Hosking DJ, Iqbal JS, McCloskeyE, Sampson D 2004 Medical management of hypercalcemia. Calcif Tissue Int 74:1-11
19. Langston AL, Ralston SH 2004 Management of Paget's disease of bone. Rheumatology (Oxford) 43:955-959
20. Fleisch H 1993 Bisphosphonates in bone disease. 1st ed. Berne, Switzerland: Stampfli
21. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Gamero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
22. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
23. Samadfam R, Xia Q, Goltzman D 2007 Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 148:2778-2787
24. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
25. Gasser JA, Kneissel M, Thomsen JS, Mosekilde L 2000 PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 1:53-56
26. Johnston S, Andrews S, Shen V, Cosman F, Lindsay R, Dempster DW, Iida-Klein A 2007 The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology 148:4466-4474
27. Samadfam R, Xia Q, Goltzman D 2007 Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55-63
28. Idris AI, Rojas J, Greig IR, van 't Hof RJ, Ralston SH 2008 Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191-201
29. Orriss, IR, Uting, JC, Key ML, Brandao-Burch A, Colston K, Arnett TR 2007 Zoledronate potently inhibits the growth, function and survival or normal rat osteoblasts. Calcif Tissue Int 80:S78
30. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M 2003 New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, orraloxifenein ovariectomizedrats. Endocrinology 144:2008-2015
31. Lin JH 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85